Literature DB >> 26528651

Cost-effectiveness of smoking cessation treatment initiated during psychiatric hospitalization: analysis from a randomized, controlled trial.

Paul G Barnett1, Wynnie Wong, Abra Jeffers, Sharon M Hall, Judith J Prochaska.   

Abstract

OBJECTIVE: We examined the cost-effectiveness of smoking cessation treatment for psychiatric inpatients.
METHOD: Smokers, regardless of intention to quit, were recruited during psychiatric hospitalization and randomized to receive stage-based smoking cessation services or usual aftercare. Smoking cessation services, quality of life, and biochemically verified abstinence from cigarettes were assessed during 18 months of follow-up. A Markov model of cost-effectiveness over a lifetime horizon was constructed using trial findings and parameters obtained in a review of the literature on quit and relapse rates and the effect of smoking on health care cost, quality of life, and mortality.
RESULTS: Among 223 smokers randomized between 2006 and 2008, the mean cost of smoking cessation services was $189 in the experimental treatment group and $37 in the usual care condition (P < .001). At the end of follow-up, 18.75% of the experimental group was abstinent from cigarettes, compared to 6.80% abstinence in the usual care group (P < .05). The model projected that the intervention added $43 in lifetime cost and generated 0.101 additional quality-adjusted life-years (QALYs), an incremental cost-effectiveness ratio of $428 per QALY. Probabilistic sensitivity analysis found the experimental intervention was cost-effective against the acceptance criteria of $50,000/QALY in 99.0% of the replicates.
CONCLUSIONS: A cessation intervention for smokers identified in psychiatric hospitalization did not result in higher mental health care costs in the short-run and was highly cost-effective over the long-term. The stage-based intervention was a feasible and cost-effective way of addressing the high smoking prevalence in persons with serious mental illness. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00136812. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26528651      PMCID: PMC4988964          DOI: 10.4088/JCP.14m09016

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  46 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

Review 2.  Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.

Authors:  Fujian Song; James Raftery; Paul Aveyard; Chris Hyde; Pelham Barton; Nerys Woolacott
Journal:  Med Decis Making       Date:  2002 Sep-Oct       Impact factor: 2.583

Review 3.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

Authors:  N F Woolacott; L Jones; C A Forbes; L C Mather; A J Sowden; F J Song; J P Raftery; P N Aveyard; C J Hyde; P M Barton
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

4.  Smoking and mortality among older men and women in three communities.

Authors:  A Z LaCroix; J Lang; P Scherr; R B Wallace; J Cornoni-Huntley; L Berkman; J D Curb; D Evans; C H Hennekens
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

5.  Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial.

Authors:  Judith J Prochaska; Stephen E Hall; Kevin Delucchi; Sharon M Hall
Journal:  Am J Public Health       Date:  2013-08-15       Impact factor: 9.308

6.  Duration of smoking abstinence and success in quitting.

Authors:  E A Gilpin; J P Pierce; A J Farkas
Journal:  J Natl Cancer Inst       Date:  1997-04-16       Impact factor: 13.506

7.  A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.

Authors:  Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George
Journal:  J Clin Psychiatry       Date:  2012-05       Impact factor: 4.384

8.  Depression, posttraumatic stress disorder, and mortality.

Authors:  Leslie S Kinder; Katharine A Bradley; Wayne J Katon; Evette Ludman; Mary B McDonell; Chris L Bryson
Journal:  Psychosom Med       Date:  2007-11-08       Impact factor: 4.312

9.  Smokers with behavioral health comorbidity should be designated a tobacco use disparity group.

Authors:  Jill M Williams; Marc L Steinberg; Kim Gesell Griffiths; Nina Cooperman
Journal:  Am J Public Health       Date:  2013-07-18       Impact factor: 9.308

10.  Smoking and health-related quality of life in English general population: implications for economic evaluations.

Authors:  Matthias Vogl; Christina M Wenig; Reiner Leidl; Subhash Pokhrel
Journal:  BMC Public Health       Date:  2012-03-19       Impact factor: 3.295

View more
  17 in total

1.  Cost-effectiveness of smoking cessation programs for hospitalized patients: a systematic review.

Authors:  Donghoon Lee; Ye-Rin Lee; In-Hwan Oh
Journal:  Eur J Health Econ       Date:  2019-08-26

2.  Treating Tobacco Dependence at the Intersection of Diversity, Poverty, and Mental Illness: A Randomized Feasibility and Replication Trial.

Authors:  Norval J Hickman; Kevin L Delucchi; Judith J Prochaska
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

3.  Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment.

Authors:  Paul G Barnett; Abra Jeffers; Mark W Smith; Bruce K Chow; Miles McFall; Andrew J Saxon
Journal:  Nicotine Tob Res       Date:  2015-05-04       Impact factor: 4.244

4.  The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model.

Authors:  Brian Chen; Gerard A Silvestri; Jennifer Dahne; Kyueun Lee; Matthew J Carpenter
Journal:  J Gen Intern Med       Date:  2022-01-28       Impact factor: 6.473

5.  Proactive tobacco treatment for veterans with posttraumatic stress disorder.

Authors:  Patrick J Hammett; Sandra J Japuntich; Scott E Sherman; Erin S Rogers; Elisheva R Danan; Siamak Noorbaloochi; Omar El-Shahawy; Diana J Burgess; Steven S Fu
Journal:  Psychol Trauma       Date:  2020-07-02

6.  Print-based self-help interventions for smoking cessation.

Authors:  Jonathan Livingstone-Banks; José M Ordóñez-Mena; Jamie Hartmann-Boyce
Journal:  Cochrane Database Syst Rev       Date:  2019-01-09

7.  Addressing Smoking in Supported Residential Facilities for People with Severe Mental Illness: Has Any Progress Been Achieved?

Authors:  Sharon Lawn; Teri Lucas
Journal:  Int J Environ Res Public Health       Date:  2016-10-10       Impact factor: 3.390

Review 8.  Smoking, Mental Illness, and Public Health.

Authors:  Judith J Prochaska; Smita Das; Kelly C Young-Wolff
Journal:  Annu Rev Public Health       Date:  2016-12-16       Impact factor: 21.981

9.  Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy ('START-Study'): study protocol of a randomized controlled trial.

Authors:  Jonas Dickreuter; Claudia Schmoor; Jürgen Bengel; Andreas Jähne; Jens A Leifert
Journal:  Trials       Date:  2020-06-23       Impact factor: 2.279

10.  The Potential Impact of Widespread Cessation Treatment for Smokers With Depression.

Authors:  Jamie Tam; Kenneth E Warner; Kara Zivin; Gemma M J Taylor; Rafael Meza
Journal:  Am J Prev Med       Date:  2021-07-07       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.